Pfizer's oral drug against Covid could be ready by 2022, says pharma giant's CEO
An oral drug for treating COVID-19 could be ready next year, Pfizer CEO Albert Bourla has said. Bourla said that the company is working on two antivirals, an oral and an injectable.
"We are actually on two, one is injectable and the other one an oral (antiviral)... Particularly the attention is on the oral for the world and of us because provides several advantages and one of them is that you don't need to go to the hospital to get the treatment of which is the case with all the injectables so far but you can get it home," Albert Bourla told CNBC in an interview on Tuesday, as cited by The Hill.
"If all goes well, and we implement the same speed that we are, and if regulators do the same, and they are, I hope that by the end of the year," Bourla added.
ALSO READ | Single vaccine dose cuts COVID-19 transmission by half: UK study
Remdesivir, which is manufactured by Gilead Sciences, is the only antiviral currently approved for use against the coronavirus. The US Food and Drug Administration (FDA) gave the drug full approval in October after it was granted emergency use authorization in May last year.
He also said the medication could be "way more effective against the multiple variants" of the virus than current options adding that the mechanism of action, of the antiviral, is not expected to be subject to mutations, "particularly because it's not acting on the spike, as we all know, all the mutations that we are hearing right now are seeing this in the proteins of the spike."
"This one doesn't work there so that allows us to believe that will be way more effective against the multiple variants. So, all good news. We are now progressing the studies and we will have more news around summer," the CEO added.
The Hill further reported that thus far, more than 121 million doses of the vaccine have been administered across the United States.
(With ANI Inputs)
ALSO READ | Third dose of COVID-19 vaccine 'likely' needed within 1 year, says Pfizer CEO
ALSO READ | Pfizer, AstraZeneca COVID vaccine jabs: 1 in 4 suffer mild side effects
